For people with multiple sclerosis (PwMS), within-person reductions in daytime activity patterns precede clinical disability worsening, according to a study published online March 4 in Neurology.

The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in ...

Wearable sensors may help identify people with multiple sclerosis (MS) who are more likely to have worsening disability and ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

In a nationwide, retrospective, population-based cohort study, data from the Swedish MS Registry for 7331 patients were analyzed. The adjusted risk of EDSS milestones 3.0, 4.0, and 6.0 were, ...

July marks Disability Pride Month, a time to commemorate the passage of the Americans With Disabilities Act and to celebrate the diversity, resilience, and visibility of the disabled community. This ...

Please provide your email address to receive an email when new articles are posted on . A study examined the effects of exercise in 3,000 patients with MS for up to 15 years. More physical activity ...

How do we assess the needs of people with severe multiple disabilities? Unable to communicate verbally and physically, this population has nearly no possibility of expressing itself. Thanks to ...

Using eye-tracking -- a technique for recording and analyzing eye movements -- a team has shown that individuals with multiple disabilities can improve their social and emotional skills. Although ...

THE health problems presented by a disease differ decidedly as they are viewed from the standpoint of the community, and from that of the patient and his physician. The primary method of study is also ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.